CYPRALIS
Discovering and developing novel medicines for acute and chronic degenerative diseases
CYPRALIS
Social Links:
Industry:
Biotechnology Health Care
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.cypralis.com
Total Employee:
51+
Status:
Active
Contact:
+441277367020
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Nginx US Privacy User Signal Mechanism Apple Mobile Web App Capable DoubleClick.Net
Similar Organizations
2-BBB Medicines BV
2-BBB Medicines BV is a created to develop medicines for the treatment of devastating brain diseases.
BCPRO.APP
We are developing novel methods of analyzing genetic data to produce actionable insights on human health
Cugene
Cugene discover and develop innovative medicines for treating cancer and inflammatory disorders.
Neurotec Pharma
Neurotec Pharma is focused on developing new treatments for acute and chronic central nervous system (CNS) diseases.
Official Site Inspections
http://www.cypralis.com
- Host name: staticip2.multiscreensite.com
- IP address: 100.24.208.97
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Cypralis"
Company Overview - Cypralis
Cypralis is privately held and started as a spinout from Selcia Ltd. in 2012. The founders are experts of combined 50 years of experience in the biology of cyclophilins and the chemistry of …See details»
Cypralis - Crunchbase Company Profile & Funding
Organization. Cypralis . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. Discovering and developing novel medicines for acute and …See details»
Board and Management - Cypralis
Cypralis Ltd, St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS, United Kingdom Company registration no. 08028515.See details»
Cypralis Company Profile 2024: Valuation, Funding
When was Cypralis founded? Cypralis was founded in 2012. Where is Cypralis headquartered? Cypralis is headquartered in Cambridge, United Kingdom. …See details»
Cypralis - Products, Competitors, Financials, Employees, …
Cypralis focuses on the development of novel medicines for acute and chronic degenerative diseases within the pharmaceutical industry. The company specializes in creating small …See details»
Cypralis - Company Profile - Tracxn
Dec 5, 2024 Cypralis - UK-based, early-stage, private biotech, developing selective PPIase inhibitors for treatment of neurodegenerative diseases, liver disease etc.. Raised funding over …See details»
Cypralis Company Profile - Office Locations, Competitors ... - Craft
Cypralis is a company discovering medicines for acute and chronic degenerative diseases. It develops small molecule drugs that inhibit cyclophilins. The company also offers therapies for …See details»
Cypralis Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Cypralis Ltd. with its drug pipeline, therapeutic area, technology platform, 1 news, Technology Platform:Small molecule drug, Drug:CC-4066, CC-1233. ... The statistics for drugs …See details»
CYPRALIS LTD - VentureRadar
Cypralis is a company focusing on discovering and developing novel medicines for acute and chronic degenerative diseases. Cypralis has assembled a collection of over 2,000 compounds …See details»
CYPRALIS LIMITED Company Profile - Dun & Bradstreet
Cypralis limited. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united kingdom / cambridge …See details»
Contact | Cypralis
Cypralis Ltd St John's Innovation Centre Cowley Road, Cambridge, CB4 0WS, UK Email: [email protected] Twitter: @cypralispharma Company registration no: 08028515See details»
Cypralis CEO and key executive team | Craft.co
Cypralis's Non-Executive Director is Nicola Baker-Munton. Other executives include Kim Haworth, CFO; Hans Fliri, Chairman/CEO and 1 others. See the full leadership team at Craft.See details»
Cypralis Ltd | Alzheimer's Drug Discovery Foundation
Cypralis has discovered new classes of cyclophilin inhibitors, some of which inhibit CypD and are protective towards cells, and others that are able to penetrate the brain but are not selective …See details»
Innovate UK grants funding to Cypralis to develop cyclophilin D ...
Jan 23, 2017 At the end of October last year, the company completed a feasibility study designed to generate new inhibitors of cyclophilin D for targeting diseases such as …See details»
Cypralis to develop new cyclophilin inhibitors for …
Mar 1, 2017 UK-based life sciences company Cypralis has secured funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to develop new cyclophilin inhibitors for …See details»
Changing Shapes: From Proteins to Business Models | Cypralis
Cypralis was spun out from parent company Selcia to exploit its extensive expertise and know-how in targeting a large family of protein targets involved in many acute and chronic diseases. …See details»
Research programme: small molecule protein inhibitors - Cypralis
Cypralis, a spin-off of Selcia, is developing peptidylprolyl isomerase inhibitors, including subtype-selective cyclophilin inhibitors, for the treatment of ... If your organization has a subscription, …See details»
Pipeline - Cypralis
The strategy of Cypralis is focused on diseases representing an unmet clinical need where the treatment is of short duration and efficacy can be established on the basis of clear and …See details»
About Cyclophilins | Cypralis
Cyclophilins are ubiquitous proteins that have important functions both inside cells and as secreted proteins. Acting as peptidyl-prolyl cis/trans isomerases they control shape transitions …See details»